Maintenance Treatment of Renal Anemia in Dialysis Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 229 participants.
Also called NCT03543657
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 229 participants
- Sponsor
- Registry
-
NCT03543657
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03543657. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-23 (actual); primary completion 2019-08-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Maintenance Treatment of Renal Anemia in Dialysis Subjects
- Acronym
- MIYABI HD-M
- Condition
- Anemia
- Condition
- Renal Insufficiency, Chronic
- Intervention (Drug)
- Molidustat (BAY85-3934)
- Intervention (Drug)
- Darbepoetin alfa
- Intervention (Drug)
- Placebo of Molidustat (BAY85-3934)
- Intervention (Drug)
- Placebo of Darbepoetin alfa
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct03543657- Content hash
4645898407eebcd36d9e5b444180cc0722390255057b4e8f69cacd6ae7a1e9fc